Zonegran / Zonisamide: Overview

Modified on 2009/10/14 21:46 by admin
Zonegran, also known as Zonisamide, is indicated for the treatment of partial seizures (or focal seizures) in adults with epilepsy. Partial seizures are limited to a specific region of the brain, with the patient remaining conscious throughout the attack. The medication reduces voltage-dependent transient inward currents, subsequently stabilizing neuronal membranes and electrical rhythms of the central nervous system. Zonegran, approved by the U.S. Food and Drug Administration (FDA) in 2000, is made by Elan Pharmaceuticals. Common side effects of Zonegran use include, but may not be limited to, drowsiness, loss of appetite, dizziness, headache, nausea, agitation and irritability.

In July 2002, the FDA and Elan added a bolded WARNING to inform healthcare professionals that pediatric patients appear to be at an increased risk for Zonegran-associated oligohidrosis and hyperthermia. Patients, especially pediatric patients, treated with Zonegran should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. The safety and effectiveness of Zonegran in pediatric patients have not been established. Zonegran is not approved for use in pediatric patients.

If you have experienced an adverse reaction after using Zonegran, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Epilepsy Drugs: Overview
  2. Balance Problems: Overview
  3. Headaches
  4. Nausea: Overview
  Name Size